Spiros Mitsopoulos, MD
Internal Medicine · Manchester, NHNPI 1720034390
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AstraZeneca at 32.8% of the total. Among internal medicine clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 124 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$645
- Novo Nordisk$394
- Amgen$180
- Lilly USA, LLC$157
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$114
- AbbVie$108
- plus $368 from 9 others
What the payments were for
- Food & beverage$1,964100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $645 |
| Novo Nordisk | 25 | $394 |
| Amgen | 10 | $180 |
| Lilly USA, LLC | 11 | $157 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $114 |
| AbbVie(2 entities) | 7 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $76 |
| Astellas Pharma US Inc | 4 | $75 |
| Sanofi-aventis U.S. LLC | 4 | $54 |
| Eisai Inc. | 3 | $42 |
| Johnson & Johnson | 2 | $33 |
| GSK | 2 | $29 |
| Abbott | 1 | $25 |
| Novartis | 2 | $22 |
| Merck | 1 | $12 |
How this compares
$1,964 in reported general payments places this provider in the 95th percentile of 504 internal medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 102 | $109,532 |
| EliquisApixaban | 35 | $50,062 |
| XareltoRivaroxaban | 27 | $29,989 |
| FarxigaDapagliflozin Propanediol | 13 | $18,818 |
| TrulicityDulaglutide | 21 | $18,651 |
| MounjaroTirzepatide | 17 | $18,062 |
| Repatha SureclickEvolocumab | 19 | $11,979 |
| MyrbetriqMirabegron | 25 | $7,952 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $6,231 |
| Clorazepate Dipotassium | 16 | $4,935 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $4,891 |
| TradjentaLinagliptin | 11 | $4,443 |
| Rosuvastatin Calcium | 189 | $3,307 |
| Humalog Kwikpen U-100Insulin Lispro | 14 | $2,269 |
| FenofibrateFenofibrate Nanocrystallized | 30 | $1,465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $394 | $109,532102 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $157 | $36,71338 claims |
| Johnson & JohnsonXarelto | $33 | $29,98927 claims |
| AstraZenecaFarxiga | $645 | $18,81813 claims |
| Astellas Pharma US IncMyrbetriq | $75 | $7,95225 claims |
| AbbVieSynthroid | $108 | $1,33834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 504 internal medicine providers in New Hampshire.
Other internal medicine in Manchester
- Amr DokmakManchester$3K
- Marcio JablonkaManchester$2K
- Frances JensenManchester$2K
- Todd MellishManchester$2K
- Kevin PorbunderwalaManchester$803
- Steven SchwartzManchester$502
- Donald RainoneLondonderry$1.9M
- Brian HyettPortsmouth$185K
- Deborah TepperLebanon$133K
- Mark HenschkeNewington$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.